Form 13-F position report

PROTAGONIST THERAPEUTICS IN

Reported by VANGUARD GROUP INC

PTGX CUSIP 74366E102 Manager CIK 0000102909

Reported 4,358,595 shares, up 81,377 (1.9%) from the prior quarter.

Reported value 16.5%; share count 1.9% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 4,358,595 Quarter-end amount reported
Reported value $240,899,545 Fair value at quarter end
Consecutive quarters held 36 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 55441000
2021-06-30 102686000
2021-09-30 41710000
2021-12-31 80307000
2022-03-31 55176000
2022-06-30 21631000
2022-09-30 24807000
2022-12-31 33796060
2023-03-31 74549739
2023-06-30 86940993
2023-09-30 53849612
2023-12-31 72319294
2024-03-31 92372650
2024-06-30 112386339
2024-09-30 189723645
2024-12-31 162893427
2025-03-31 206846263
2025-06-30 240899545
2025-09-30 282807724
2025-12-31 472831684

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for PROTAGONIST THERAPEUTICS IN held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 5,413,690 +1,156,461 (27.2%) < 0.01% $472,831,684 2026-01-29
Q3 2025 Reduced 4,257,229 -101,366 (-2.3%) < 0.01% $282,807,724 2025-11-07
Q2 2025 Added 4,358,595 +81,377 (1.9%) < 0.01% $240,899,545 2025-08-11
Q1 2025 Added 4,277,218 +57,181 (1.4%) < 0.01% $206,846,263 2025-05-09
Q4 2024 Added 4,220,037 +3,956 (0.1%) < 0.01% $162,893,427 2025-02-11
Q3 2024 Added 4,216,081 +972,608 (30.0%) < 0.01% $189,723,645 2024-11-13
Q2 2024 Added 3,243,473 +50,502 (1.6%) < 0.01% $112,386,339 2024-08-13
Q1 2024 Added 3,192,971 +39,055 (1.2%) < 0.01% $92,372,650 2024-05-10
Q4 2023 Reduced 3,153,916 -74,478 (-2.3%) < 0.01% $72,319,294 2024-02-14
Q3 2023 Added 3,228,394 +80,639 (2.6%) < 0.01% $53,849,612 2023-11-14
Q2 2023 Reduced 3,147,755 -93,538 (-2.9%) < 0.01% $86,940,993 2023-08-14
Q1 2023 Added 3,241,293 +143,579 (4.6%) < 0.01% $74,549,739 2023-05-15
Q4 2022 Added 3,097,714 +154,947 (5.3%) < 0.01% $33,796,060 2023-02-10
Q3 2022 Added 2,942,767 +208,002 (7.6%) < 0.01% $24,807,000 2022-11-14
Q2 2022 Added 2,734,765 +404,691 (17.4%) < 0.01% $21,631,000 2022-08-12
Q1 2022 Reduced 2,330,074 -18,092 (-0.8%) < 0.01% $55,176,000 2022-05-13
Q4 2021 Reduced 2,348,166 -5,620 (-0.2%) < 0.01% $80,307,000 2022-02-14
Q3 2021 Added 2,353,786 +65,752 (2.9%) < 0.01% $41,710,000 2021-11-12
Q2 2021 Added 2,288,034 +147,487 (6.9%) < 0.01% $102,686,000 2021-08-13
Q1 2021 Added 2,140,547 +122,910 (6.1%) < 0.01% $55,441,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

323 managers reported PROTAGONIST THERAPEUTICS IN for Q2 2025.

Managers reporting PROTAGONIST THERAPEUTICS IN in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 9,630,341 -106,426 0.01% $532,268,963 4 qtrs
FARALLON CAPITAL MANAGEMENT LLC Added 6,172,006 +65,000 1.43% $341,126,772 31 qtrs
RTW INVESTMENTS LP Added 5,756,277 +36,862 4.53% $318,149,430 24 qtrs
VANGUARD GROUP INC This report Added 4,358,595 +81,377 < 0.01% $240,899,545 36 qtrs
Deep Track Capital LP Added 3,245,899 +245,899 5.75% $179,400,838 3 qtrs
BVF INC IL Added 3,211,041 +636,026 6.34% $177,474,236 10 qtrs
STATE STREET CORPORATION Added 3,207,543 +500,924 < 0.01% $177,280,902 36 qtrs
UBS Group AG Added 2,501,251 +2,148,380 0.02% $138,244,142 36 qtrs
JOHNSON & JOHNSON Unchanged 2,449,183 0 40.83% $136,395,001 16 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,444,230 +20,671 < 0.01% $79,833,120 36 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 11, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
69,367
None
4,289,228

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.